CD274 and glioblastoma: While there are many ongoing Phase I and II clinical trials targeting PD-1/PD-L1, preliminary results in patients with recurrent GBM demonstrate unpredictable efficacy, with meager to no survival benefit compared to standard therapies [45,46,47].